The DIAN Trials Unit is nearing the end of its first two secondary prevention trials. It has begun a cognitive run-in period for its next trial, of a tau-based drug, and for a primary prevention study in people as young as 18.
Sharp at 100+? Thank You, Genes. Thank You, Immune System. In Hydrocephalus, Does Slow Drainage Cause Dementia? Differential Diagnosis: Can Synaptic Proteins Get It Done? Kuopio Alzheimer Symposium (9th) and Nordic Memory Clinic Conference (3rd)
At AAIC, secondary endpoint data from the API Colombian study showed trends favoring crenezumab, while people taking gantenerumab in open-label extensions declined more slowly than matched controls.
The inaugural Holloway Summit, hosted by AFTD, focused on the development of digital health technologies to track the progression of FTD’s myriad manifestations.
In collaboration with the Banner Alzheimer’s Institute, Eli Lilly will test the anti-amyloid immunotherapy in cognitively normal people with a high risk for AD based on plasma phospho-tau-217.
A liposomal anti-tau vaccine elicited a response against disease-linked forms of tau, outdoing a conjugated vaccine. A separate tack to vaxx against tau is waiting in the wings.
Adding to our collection of APP, Presenilin, Tau, and Trem2 mutations, the new dataset curates neurologic and non-neurologic information, ranging from clinical to molecular.
New data presented at the AD/PD conference offer the first evidence that a brain-shuttle strategy can work in people; the lecanemab and aducanumab antibody programs offer small updates.